Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Total Liabilities (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Total Liabilities data on record, last reported at $13.5 million in Q1 2026.

  • On a quarterly basis, Total Liabilities fell 4.91% to $13.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $13.5 million, a 4.91% decrease, with the full-year FY2025 number at $17.3 million, down 2.26% from a year prior.
  • Total Liabilities reached $13.5 million in Q1 2026 per FULC's latest filing, down from $17.3 million in the prior quarter.
  • Over the last five years, Total Liabilities for FULC hit a ceiling of $34.5 million in Q2 2022 and a floor of $13.5 million in Q1 2026.
  • A 5-year average of $21.8 million and a median of $21.7 million in 2024 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: rose 27.75% in 2022, then dropped 29.35% in 2025.
  • Tracing FULC's Total Liabilities over 5 years: stood at $27.7 million in 2022, then fell by 18.89% to $22.5 million in 2023, then fell by 21.41% to $17.7 million in 2024, then dropped by 2.26% to $17.3 million in 2025, then fell by 22.08% to $13.5 million in 2026.
  • Business Quant data shows Total Liabilities for FULC at $13.5 million in Q1 2026, $17.3 million in Q4 2025, and $16.5 million in Q3 2025.